Keywords: palonosetron, prevents, cinv, boosts, food, intake, highly-emetogenic
Palonosetron prevents CINV and boosts food intake in highly-emetogenic chemo patients, study finds
Article | 30 March 2009
A new, innovative study shows that a single dose of Swiss drugmaker Helsinn's palonosetron plus dexamethasone not only prevents chemotherapy-induced ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- New Zealand declines Alexion's funding application for Solaris
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Elan makes "transformational" acquisitions and a divestment
